Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Mar 10, 2015 7:36pm
189 Views
Post# 23507622

RE:Major deal transactions

RE:Major deal transactionsmasila, thanks for this perspective. I have not yet had a chance to review the link but your points wring true.

In an entirely unrelated business, social media marketing and digital marketing I'm seeing huge valuations on businesses like Twitter (monthly user log in of 288 million) with a market valuation of $26 billion but it is unprofitable and it's rate or growth (new sign ups) is declining. Shareholders are unhappy.

Even Uber and airbnb have huge bases of users but are still in the mode of trying to make money. These seem to me to be more viable and will work out their bugs but they are already being attacked from competitors and the regulatory markets.

We all know how these companies when they are private get their valuations - private investors (big ones like Google, etc) buying a small number of shares at an agreed subjective price which is then multiplied by the size of the private float to create the valuation...all in prep for the IPO.

So I understand, with the risk of biomed stocks, and the binary end point of trial results to the stock market why share prices are underestimated.

But it sure is frustrating to me to see such important ventures as biomed are undervalued compared to something as frivolous and fleeting as social media.

Just thinking out loud again. Sex appeal wins the day.

Cheers
Toinv
Bullboard Posts